Logo image of ERNA

ERNEXA THERAPEUTICS INC (ERNA) Stock Fundamental Analysis

NASDAQ:ERNA - Nasdaq - US1140823089 - Common Stock - Currency: USD

1.7  +0.01 (+0.59%)

Fundamental Rating

1

Overall ERNA gets a fundamental rating of 1 out of 10. We evaluated ERNA against 551 industry peers in the Biotechnology industry. ERNA may be in some trouble as it scores bad on both profitability and health. ERNA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ERNA had negative earnings in the past year.
ERNA had a negative operating cash flow in the past year.
ERNA had negative earnings in each of the past 5 years.
ERNA had a negative operating cash flow in each of the past 5 years.
ERNA Yearly Net Income VS EBIT VS OCF VS FCFERNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of ERNA (-911.44%) is worse than 97.46% of its industry peers.
Industry RankSector Rank
ROA -911.44%
ROE N/A
ROIC N/A
ROA(3y)-333.38%
ROA(5y)-301.4%
ROE(3y)-1264.52%
ROE(5y)-959.07%
ROIC(3y)N/A
ROIC(5y)N/A
ERNA Yearly ROA, ROE, ROICERNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

1.3 Margins

ERNA has a Gross Margin of 93.46%. This is amongst the best in the industry. ERNA outperforms 94.56% of its industry peers.
In the last couple of years the Gross Margin of ERNA has grown nicely.
ERNA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y6.07%
ERNA Yearly Profit, Operating, Gross MarginsERNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

0

2. Health

2.1 Basic Checks

ERNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
ERNA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ERNA has been increased compared to 5 years ago.
There is no outstanding debt for ERNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ERNA Yearly Shares OutstandingERNA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
ERNA Yearly Total Debt VS Total AssetsERNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -76.77, we must say that ERNA is in the distress zone and has some risk of bankruptcy.
ERNA has a worse Altman-Z score (-76.77) than 95.64% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -76.77
ROIC/WACCN/A
WACC9.73%
ERNA Yearly LT Debt VS Equity VS FCFERNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

ERNA has a Current Ratio of 0.21. This is a bad value and indicates that ERNA is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of ERNA (0.21) is worse than 95.28% of its industry peers.
ERNA has a Quick Ratio of 0.21. This is a bad value and indicates that ERNA is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of ERNA (0.21) is worse than 95.10% of its industry peers.
Industry RankSector Rank
Current Ratio 0.21
Quick Ratio 0.21
ERNA Yearly Current Assets VS Current LiabilitesERNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for ERNA have decreased strongly by -46.89% in the last year.
The Revenue has grown by 369.30% in the past year. This is a very strong growth!
Measured over the past years, ERNA shows a very negative growth in Revenue. The Revenue has been decreasing by -50.61% on average per year.
EPS 1Y (TTM)-46.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.51%
Revenue 1Y (TTM)369.3%
Revenue growth 3YN/A
Revenue growth 5Y-50.61%
Sales Q2Q%-100%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ERNA Yearly Revenue VS EstimatesERNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2023 2024 5M 10M 15M 20M 25M
ERNA Yearly EPS VS EstimatesERNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2021 0 -500 -1K -1.5K -2K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ERNA. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ERNA Price Earnings VS Forward Price EarningsERNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ERNA Per share dataERNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ERNA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ERNEXA THERAPEUTICS INC

NASDAQ:ERNA (8/6/2025, 2:29:22 PM)

1.7

+0.01 (+0.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12
Earnings (Next)08-11 2025-08-11
Inst Owners2.39%
Inst Owner Change-17.1%
Ins Owners9.45%
Ins Owner Change59.64%
Market Cap12.51M
Analysts43.33
Price TargetN/A
Short Float %1.85%
Short Ratio0.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 23.39
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-93.66
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.96
FCFYN/A
OCF(TTM)-1.92
OCFYN/A
SpS0.07
BVpS-0.81
TBVpS-1.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -911.44%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.46%
FCFM N/A
ROA(3y)-333.38%
ROA(5y)-301.4%
ROE(3y)-1264.52%
ROE(5y)-959.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y6.07%
F-Score4
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.21
Quick Ratio 0.21
Altman-Z -76.77
F-Score4
WACC9.73%
ROIC/WACCN/A
Cap/Depr(3y)70.57%
Cap/Depr(5y)70.45%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-46.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.51%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)369.3%
Revenue growth 3YN/A
Revenue growth 5Y-50.61%
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y32.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.47%
OCF growth 3YN/A
OCF growth 5YN/A